alzheimer's
Aug 26, 2016
Denali’s Impressive Research Portfolio
The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
